NeuroOne® Announces Change of Virtual Investor Webinar to Friday, January 10, 2024
Company to Provide Overview of Business Model and Expected Revenue Acceleration in Fiscal Year 2025 EDEN PRAIRIE, Minn., Jan. 06,...
Brain
Rakovina Therapeutics Announces Receipt of AI-Derived Drug Candidates and Advancement to Preclinical Validation
VANCOUVER, British Columbia, Jan. 06, 2025 (GLOBE NEWSWIRE) -- Rakovina Therapeutics Inc. (TSX-V: RKV), a biopharmaceutical company focused on the...
Fortress Biotech and Cyprium Therapeutics Announce U.S. FDA Acceptance and Priority Review of NDA for CUTX-101 for Treatment of Menkes Disease
Priority review granted for CUTX-101 with PDUFA target action date set for June 30, 2025 Cyprium is eligible to receive...
Emerging Specialty EHR Vendors Transform Clinical Workflows With Tailored Solutions, Insights From Black Book Research
54 Specialty EHR Vendors Across 17 Categories Mark New Entries in the 2024 Black Book Surveys with High Satisfaction Marks...
National Sleep Foundation Launches into 35th Year Advancing Sleep Health
Marks Ten Years Since First Championing the Promise of SleepTech® at CES WASHINGTON, Jan. 3, 2025 /PRNewswire/ -- National Sleep Foundation...
NeuroOne® Announces Virtual Investor Webinar on January 9, 2025 at 11:00 a.m. EST
Company to Provide Overview of Business Model and Expected Revenue Acceleration in Fiscal Year 2025 EDEN PRAIRIE, Minn., Jan. 03,...
Silo Pharma Issues Letter to Shareholders Detailing Development Progress and Potential for Lead Assets Targeting PTSD and Chronic Pain
IND submission for intranasal SPC-15 treatment expected in 2025; Phase 1 clinical trial to follow upon approvalSP-26 ketamine implants nearing...
Neumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive Disorder
Study did not demonstrate statistically significant improvement on primary endpoint of reduction in depressive symptoms as measured by MADRS total...
Firefly Neuroscience Closes on Financing of up to $12.4 Million
TORONTO, Dec. 31, 2024 (GLOBE NEWSWIRE) -- Firefly Neuroscience, Inc. (“Firefly,” “we,” or the “Company”) (NASDAQ: AIFF), an Artificial Intelligence...
AI Wellness Launches Groundbreaking 2025 Initiatives to Celebrate Visionaries, Innovators, and Clinics
LAS VEGAS, Dec. 30, 2024 /PRNewswire/ -- Assisted Intelligence Wellness Inc. (AI Wellness), a global leader in integrating AI with personalized...
Microbot Medical® Concludes 2024 by Achieving Key Milestones Culminating in FDA Submission for the Commercialization of LIBERTY®
Company Shifts Focus to Preparing for Commercial Launch as it Enters 2025BRAINTREE, Mass., Dec. 30, 2024 (GLOBE NEWSWIRE) -- Microbot...
Radiopharm Announces Strategic Co-Development Partnership with Lantheus for Australia
RAD to advance the clinical development of Lantheus innovative radiopharmaceuticals in Australia Initial collaboration will focus on a Phase 1...
Vincerx Pharma Enters into a Binding Term Sheet for a Strategic Merger with Oqory, Inc.
Proposed merger would add a differentiated Phase 3 TROP2 Antibody-drug Conjugate (ADC) to the combined company’s pipelinePALO ALTO, Calif., Dec....
NAVIGANTIS VASCO™ Robotic Platform Used with First Patients Enrolled in Neurovascular Study
MIAMI, Dec. 27, 2024 /PRNewswire/ -- Navigantis Inc. announced today the first successful neurovascular clinical cases performed with its VASCO interventional...
Honeycomb Clinic Positions for Public Offering
Medical Co-working space challenges broken healthcare system. HOUSTON, TEXAS / ACCESSWIRE / December 23, 2024 / Honeycomb Clinic, the innovative...
Telomir Pharmaceuticals Confirms Copper Binding Capabilities of Telomir-1 and Expands Pipeline Into Wilson’s Disease
MIAMI, FL / ACCESSWIRE / December 23, 2024 / Telomir Pharmaceuticals, Inc. (NASDAQ:TELO), or the "Company", an emerging leader in...
Mentavi Health Offers Tips and Tools to Help Manage Stress During the Holiday Season
Nearly half of all Americans feel more pressure from time commitments, stretched finances, gift-giving, and family gatherings. Mentavi, a leader...
RAD 202 Receives Approval to Start Phase 1 Therapeutic Trial
Ethics approval received in Australia for the initiation of RAD’s Phase 1 therapeutic trial of 177Lu-RAD202 in Breast and Gastric...
Darmiyan Enters Medicare GUIDE Program Through Partnership with Five Star Home Health Care, CareBrains, and Brain Watch Coalition
SAN FRANCISCO, Dec. 19, 2024 /PRNewswire/ -- Darmiyan, Inc., a leader in brain health technology, proudly announces its participation in...
Lexaria’s Registered GLP-1 Study #4 Begins Dosing
Registered Phase-1b 12-week study will investigate safety, diabetes control, and weight loss KELOWNA, BC / ACCESSWIRE / December 19, 2024...